Top Tweets for #Exebacase
Las #LISINAS ✂️:Moléculas esperanzadoras en ayudar a antibióticos🤝,pero una d ellas #Exebacase +antibiótico NO superior a SOLO antibiótico en bacteriemia/endocarditis🩸🫀x SARM🛡️🍇 @CIDJournal. In Vitro SI buenos resultados pero no siempre correlacion😢https://t.co/ytQUNN0vpw
#Exebacase is a novel direct lytic agent (#lysin) under clinical development – a purified protein produced from a gene originally cloned from #bacteriophage such that the final product is devoid of phage material. Exebacase has activity against all staph species, with potent activity against staphylococcal #biofilm. Proud to have included @CrioacLyon @CHUdeLyon the 1st patient in this unique monocentric trial in 🇫🇷 and to propose it after debridement under #arthroscopy to our patients with prosthetic joint infection due to either S. aureus or coagulase negative staphylococci. ⬇️
https://t.co/7SqCDuZLFg
Focus on #exebacase PH3 & interim futility in July: also presented 2 posters @ASMicrobiology #ASM2022. $CFRX compiles data w/ potential to show utility of exebacase against #antibioticresistant staphylococcus in a variety of settings & our #DLA platform https://t.co/1qUUTpy6br
$CFRX PH3 DISRUPT milestone! Exceeded 60% enrollment of #MRSA pts needed for #DSMB to progress w/ interim futility analysis & assess #exebacase superiority on primary efficacy endpoint. Data to DSMB early July. Incredible effort by CF team during pandemic. https://t.co/EMAgHuBQJQ
Big lineup @ #ECCMID2022: $CFRX selected for oral presentation & six posters. New data will highlight lead candidate #exebacase in #PH3 superiority study, #CF370 our engineered lysin, & lead compounds in our amurin peptide program. See you live or online!
https://t.co/xh7XU7HsDo
.@TheLancet global perspective on #AMR: BSI #2 in frequency of occurrence & 1 of 3 infections that lead to 78% of all AMR deaths. "In 2019 methicillin-resistant #Saureus was pathogen–drug combo w/100K+ deaths & 3.5M DALYs. #Exebacase on path to meet need.
https://t.co/G15oOco8x2
NEWS: @CF_Foundation awarded $CFRX addtl. funding to investigate #exebacase to treat serious #MRSA lung infections for #CysticFibrosis. MRSA's prevalence in #cf grown - ⬆️9.2% in 2002 to 25.9% in 2017; major cause of lung function ⬇️ & mortality in CF pts.
https://t.co/8M6zIfJ0b4
Clinical Infectious Diseases @IDSAInfo: $CFRX 1st #DLA #exebacase & peds MRSA; 5 mos. infant after evaluation @DukeU confirmed w/#MRSA & pt. could not clear w/SOC antibiotics; life-threatening. MD obtained emergency use to treat. Motivating, trials planned https://t.co/nUdLaEIqwV
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent #Exebacase to Treat #MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases https://t.co/ZL0bwMbHvq $CFRX
.#Exebacase, an anti-staphylococcal #lysin produced from a #bacteriophage-encoded #gene, is a promising adjunctive therapy for severe #methicillin-resistant #Staphylococcus aureus #infections.
If the technology you developed saves but one life, it was worth the effort. Success in compassionate use is a hint of where this may be going. #phagelysins #lysins #lysintherapy https://t.co/VTk659cjQq
@KolendaCamille has presented @EBJIS_ 2021 in 🇸🇮 the synergistic anti #biofilm effect of #exebacase (CF-301 #phage derived #lysins) with antibiotics against #staph epidermidis. A strong basis to use this lysin locally in patients with prosthetic-joint infections @CrioacLyon!
Check out our $CFRX CEO interview: Roger Pomerantz discusses engineered lysins, #exebacase's role as new modality causing a paradigm shift as an #antimicrobial, & ContraFect's next candidate #CF370 targeting #PseudomonasAeruginosa. Great recap of our mission and clinical focus!
This weeks feature - In a bid to counter the next great health crisis, ContraFect is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs). $CFRX https://t.co/Cn5qudFb7l
ICYMI: CEO Roger Pomerantz talks $CFRX "trifecta" superiority vs SOC @ Cantor Global HC - #exebacase focus: clinical response, reduced mortality, & health economics critical in superiority & for anti-infective success. Partnerships w/ @BARDA & @pfizer key
https://t.co/6A74QntSs3
$CFRX @IDWeek2021: will deliver late breaker oral presentation on rapid symptom resolution in adult pts w/Staph aureus bacteremia, treated w/#exebacase in completed Ph2, Dr. Cara Cassino, our CMO will present. Also poster on exebacase, Staph aureus & #MRSA https://t.co/8gOwaBlhVS
New data @ESCMID #ECCMID2021: #exebacase, #PH3 w/ Breakthrough Therapy Designation for #MRSA, has potential to treat Staph bone & joint infections. #CF370 1st engineered lysin shows activity against #MultiDrugResistant #GramNeg. $CFRX programs move forward
https://t.co/1bo3h1Xxkn
Arthroscopie lavage @CrioacLyon @CHUdeLyon avec administration locale de CF-301 (#phage #Lysin appelé #Exebacase @ContraFectCorp 🇺🇸) chez 4 patients âgés atteints d'une infection récidivante du genou à S. epidermidis multiresistant https://t.co/t8YcjyNb5t
Arthroscopic “Debridement and Implant Retention” with local administration of #Exebacase (#phage #Lysin called CF-301 from @ContraFectCorp) @CrioacLyon @CHUdeLyon in 4 elderly patients with relapsing multiresistant S. epidermidis prosthetic knee infection https://t.co/t8YcjyNb5t
Congrats @Bayer: demonstrated superior efficacy in Copanlisib/CHRONOS-3 trial. This is superiority paradigm we strive for in #infectiousdiseases w/PH3 DISRUPT study; structured to show superiority of #exebacase + SOC & over SOC alone, superiority is goal!
https://t.co/ar7JPU65RT
Elated & gratified: largest funding @BARDA to date $CFRX awarded $86.8M. $9.8M initially for PH3 #exebacase superiority study in pts w/ Staph aureus & up to $77M more w/ potential FDA approval/post-approval milestones. Interim analysis slated 2nd half 2021
https://t.co/6kQqbJ46cl
Last Seen Hashtags on Sotwe
見せ合い
Seen from Japan
ometv
Seen from Philippines
nolimit() +filter:native_video #momson
Seen from Turkey
radioapple
Seen from Poland
siblings
Seen from Japan
monkeyapp
Seen from Mexico
mama #porn filter:videos
Seen from Poland
loli cunny
Seen from Turkey
Boruto153
Seen from United States
HEATEDRIVALRY
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.8M followers
Taylor Swift
@taylorswift13
81.7M followers
Lady Gaga
@ladygaga
73.2M followers
Virat Kohli
@imvkohli
70.1M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
62.9M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
60.9M followers
X
@x
60.8M followers